3ο Συνέδριο Ογκολογίας της Διασποράς

Τα πιστοποιητικά είναι διαθέσιμα!
Δεν υπάρχουν διαθέσιμα δεδομένα. Επικοινωνήστε μαζί μας μέσω email ζητώντας την πιστοποίησή σας ή καλέστε μας για να σας βοηθήσουμε.

Moderators: I. Boukovinas (GR), Τh. Makatsoris (GR)

09.00-09.20 Integration of clinical parameters for adjuvant chemotherapy decision making   D. Papamichael (CY)

09.20-09.40 Defining post-operative management of patients with early-stage colorectal cancer using the “Immunoscore”   I. Souglakos (GR)

09.40-10.00 The integration of ctDNA in the post-operative treatment of patients with early-stage colorectal cancer   N. Tsoulos (GR)

10.00-10.20 From Endometrial to Rectal Cancer: Maximizing the benefit of Immunotherapy in dMMR tumors   Ι. Athanasiadis (GR)

10.20-10.35 Discussion

Moderators: V. Georgoulias (GR), M. Kalofonou (UK)

11.00-11.20 Update of clinical relevance of CTCs and ctDNA in breast cancer               E. Lianidou (GR)

11.20-11.40 The emerging value of liquid biopsy for the monitoring of MRD in NSCLC P. Christopoulos (DE)

11.40-12.00 The liquid biopsy as a new tool in the management of oncogene-driven advanced/metastatic NSCLC    G. Tsakonas (SE)

12.00-12.15 Discussion

Moderators: H. Gogas (GR), D. Bafaloukos (GR)

12.15 -12.35 An update on the pathologic diagnosis of melanoma   K. Linos (US)

12.35 -12.55 Adjuvant treatment in Melanoma - Latest evidence.  P. Koliou (UK)

12.55 -13.15 Metastatic melanoma treatment: Combining old and new therapies           A. Schiza (SE)

13.15 -13.30 Discussion

Moderators: V. Papadimitrakopoulou (US), P. Kosmidis (GR)

14.30-15.00 A. Pallis (DE), V. Pelekanou (US)

15.00-15.30 D. Iliopoulos (US/GR), K. Kosmatopoulos (FR), K. Vougas (GR)

15.30-16.00 Μ. Giannakis (US), M. Ignatiadis (BE), E. Andreopoulou (US)

Moderators: Z. Saridaki (GR), F. Dimitrakopoulos (GR)

16.00-16.20 Pembrolizumab for the treatment of early-stage disease   V. Karantza (US)

16.20-16.25 Q & A

16.25-16.45 Individualized combinatorial treatments, biomarkers and toxicity in oncology   G. Vasmatzis (US)

16.45-16.50 Q & A

16.50-17.10 OncoSeek for the early detection of cancer   N. Papadopoulos (US)

17.10-17.15 Q & A

17.15-17.35 Identification and development of a novel, olive-oil derived, small molecule lipid metabolism inhibitor, against solid tumors   D. Iliopoulos (US)

17.35-17.40 Q & A

Moderators: Ch. Kittas (GR), I. Athanasiadis (GR)

18.00-18.20 New Horizons in Neurooncology Research   Ev. Galanis (US)

18.20-18.25 Q & A

18.25-18.45 Proper engagement of international “Greek” talent in Oncology               G. Pavlakis (US)

18.45-18.50 Q & A

18.50-19.10 New approaches in the treatment of malignancies   L. Platanias (US)

19.10-19.15 Q & A

Moderators: Ev. Galanis (US), G. Vasmatzis (US)

The Human Genome Program: A Revolution in Biological Research    A. Patrinos (US)

Moderators: N. Hatzinikolaou (GR), Ch. Christopoulos (FR)

Gemistus Plethon, Basilius Bessarion the Trepizond & El Greco: Three Greeks of Diaspora - Three pivotal starting points for Western Civilization   Th.Triaridis (GR)

Moderators: Th. Foukakis (SE), M. Rovithi (GR)

08.20-08.40 The emerging need for the generalized molecular comprehensive profiling of the tumor in clinical practice.  K. Papadimitriou (BE)

08.40-09.00 Methylation as an alternative mechanism to induce HRD   A. Klinakis (GR)

09.00-09.30 The increasing relevance of RARP inhibition for the treatment of solid tumor    M. Liontos (GR)

09.30-09.50 New roads for the clinical evolution of PARP inhibitors in oncology           S. Linardopoulos (UK)

09.50-10.00 Discussion 

Moderators: D. Filippou (GR), Ι. Boukovinas (GR)

10.00-10.15 Athens LifeTech Park: A innovation hub for biotechnology & precision medicine in Greece (ELPEN)   D. Iliopoulos (US)

10.15-10.30 Investing in biotechnology: innovation with multiplier effect for Greece (DEMO)   V. Paretzoglou (GR)

10.30-10.45 Pfizer’s global Center for Digital Innovation in Thessaloniki: Accelerating the race in digital pharma   N. Gariboldi (GR)

10.45-11.00 Precision Medicine and the ”Genome of Greece”   D. Thanos (GR)

11.00-11.15 Discussion

Moderators: I. Souglakos (GR), I. Athanasiadis (GR)

11.45-12.00 TBD    S. Gennatas (UK)

12.00-12.15 Clinical implementation of molecular subtyping for bladder cancer               P. Tsantoulis (CH)

12.15-12.30 Improved monitoring of ALK+ lung cancer using circulating DNA analysis      P. Christopoulos (DE)

Moderators: E. Andreopoulou (US), T. Mamounas (US)

14.20-14.40 HER2-low Breast Cancer: Challenges and Opportunities   K. Siziopikou (US)

14.40-15.00 Biomarkers for the treatment of metastatic breast cancer    V. Kaklamani (US)

15.00-15.20 Latest advances in ER+ metastatic breast cancer   M. Ignatiadis (BE)

15.20-15.40 Immunotherapy: A new emerging tool for the treatment of breast cancer A. Matikas (SE)

15.40-15.50 Discussion

Moderators: A. Kotsakis (GR), N. Karachaliou (DE)

15.50-16.10 Recent therapeutic evolution for the treatment of oncogene-driven NSCLC H. Charalambous (CY)

16.10-16.30 The evolution of immunotherapeutic approach in NSCLC  D. Papadatos-Pastos (UK)

16.30-16.50 Perspectives of the radiotherapy/immunotherapy combination  H. Gkika (DE)

16.50-17.10 The evolution of the treatment landscape in SCLC   K. Leventakos (US)

17.10-17.20 Discussion

Moderators: P. Anastasiadis (US), G. Patrinos (GR)

18.10-18.30 Strategies for overcoming resistance to TKIs   F. Skoulidis (US)

18.30-18.50 Mechanisms of resistance to Antibody-Drug Conjugates   A. Patrikidou (FR)

18.50-19.10 Resistance to immunotherapy   N. Karachaliou (DE)

19.10-19.25 Discussion

Moderators: P. Tsantoulis (CH), A. Boutis (GR)

19.25-19.45 Advances in the management of the metastatic castration resistant prostate cancer   Ε. Antonarakis (US)

19.45-20.05 The new therapeutic landscape of metastatic transitional cell carcinoma of the bladder    P. Grivas (US)

20.05-20.25 The value of TKIs for the management of metastatic renal cell carcinoma in the era of immunotherapy   K. Koutsoukos (GR)

20.25-20.45 Novel immunotherapy strategies for the treatment of renal cell carcinoma A. Drakaki (US)

20.45-20.55 Discussion

Moderators: D. Thanos (GR), P. Makrythanasis (GR)

Genetics and cancer.       S. Antonarakis (CH) 

Moderators: O. Tsitsilonis (GR), I. Pateras (GR)

11.00-11.20 Tumor Immunology    S. Karagiannis (UK)

11.20-11.40 Immune responses in tumour and lymph nodes of patients with triple negative breast cancer    A. Grigoriadis (UK)

11.40-12.00 Towards precision oncology via machine learning methods   S. Tsoka (UK) 

Moderators: A. Valachis (SE), I. Athanasiadis (GR), O.I. Zoras (GR)

14.00-14.30 Navigating the publishing landscape with Nature Cancer    Α.Ι. Zaromytidou (US)

14.30-15.00 The emerging importance of NSCLC Heterogeneity   V. Anagnostou (US)

Discussion on future collaborations - New ideas

Technical Support is available:
- everyday 09:00-17:00
- at the day of the event 09:00-21:00
For Technical Support please contact us:
Phone: +30 210 72 40 039
Email: support@livetime.gr

Event Details